Remove 2022 Remove Heart Failure Remove Hypertension
article thumbnail

Cardiovascular outcomes in long COVID-19: a systematic review and meta-analysis

Frontiers in Cardiovascular Medicine

Systematic search conducted without language restrictions from December 1, 2019 to June 31, 2022 on PubMed, EMBASE, Web of Science, Cochrane library, ProQuest Coronavirus Research Database, COVID-19 Living Overview of the Evidence (L-OVE) subset of Episteminokos and the World Health Organization (WHO) Covid-19 databases.

article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan is approved in 60 countries outside the United States for use in hospitalized patients with acutely decompensated heart failure. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Allina Health’s Abbott Northwestern Hospital is First in Minnesota to Implant Barostim Therapy to Improve Symptoms of Heart Failure

DAIC

Barostim is the world’s first FDA-approved neuromodulation heart failure device, which works by stimulating baroreceptors — natural sensors located in the wall of the carotid artery, according to CVRx. In November, 2022, the company launched its new Barostim NEO2 IPG. and Allina Health. and Allina Health. and Allina Health.

article thumbnail

Right Ventricular?Vascular Uncoupling Predicts Pulmonary Hypertension in Clinically Diagnosed Heart Failure With Preserved Ejection Fraction

Journal of the American Heart Association

Journal of the American Heart Association, Ahead of Print. BackgroundPulmonary hypertension (PH) is highly prevalent in patients with heart failure with preserved ejection fraction (HFpEF), and it is a strong predictor of adverse outcomes.

article thumbnail

Allina Health Minneapolis Heart Institute is First in Minnesota to Implant Barostim Therapy to Improve Symptoms of Heart Failure

DAIC

A team at Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital has successfully completed the first Barostim Baroreflex Activation Therapy implant in the state of Minnesota, according to an announcement from CVRx, Inc. In November, 2022, the company launched its new Barostim NEO2 IPG. and Allina Health.

article thumbnail

Validation of Post-Capillary PH Definition in HF

American College of Cardiology

What is the impact and prognostic value of the new 2022 European guideline definition of post-capillary pulmonary hypertension (pcPH) in heart failure (HF), which lowered the level of mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR)?

article thumbnail

Forecasting the Economic Burden of Cardiovascular Disease and Stroke in the United States Through 2050: A Presidential Advisory From the American Heart Association

Circulation

Annual inflation-adjusted (2022 US dollars) health care costs of cardiovascular risk factors are projected to triple between 2020 and 2050, from $400 billion to $1344 billion.